期刊文献+

HPLC测定片剂中阿戈美拉汀的含量 被引量:4

Determination of Agomelatine in Tablets by HPLC
原文传递
导出
摘要 目的采用HPLC测定片剂中阿戈美拉汀的含量。方法色谱柱为PhenomenexLuna-C18(250mmx4.6mm,5μm),流动相为甲醇-0.05mol·L-磷酸二氢钠溶液(40:60),流速为1.0mL·min-1,检测波长为230nm,柱温为25℃。结果线性回归方程为Y=I.979×100,-1.258×10^4(r=0.9999,n=5),线性范围为1.07-10.7μg·mL^-1,平均回收率为98.73%(n=9),RSD为1.28%。结论所建方法简便、准确、专属,可用于片剂中阿戈美拉汀的含量测定。 OBJECTIVE To establish a method for the content determination of Agomelatine tablets by HPLC. METHODS The HPLC method was performed on Phenomenex Luna-C18 column (250 mm×4.6mm, 5μm) with mobile phase of methanol-0.05 mol.L-1 sodium dihydrogen phosphate (40 : 60). Flow rate was 1.0 mL.min-1. Detective wavelength was set at 230 nm and the column temperature was set at 25℃. RESULTS The calibration curve of Agomelatine was linear Y=1.979 ×105X-1.258×104 (r=0.999 9, n=5) in the range of 1.07-10.7μg.mL-1. The average recovery of Agomelatine was 98.73% (n=9) with RSD of 1.28%. CONCLUSION The method is simple, accurate, specific and it can be used for the determination of the content of Agomelatine tablets.
出处 《中国现代应用药学》 CAS CSCD 2012年第7期652-655,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 阿戈美拉汀 高效液相色谱法 含量测定 Agomelatine HPLC content determination
作者简介 王毓菁,女,硕士生Tel:13815894302E-mail:lollipopwyj@126.com 通讯作者:张根元,男,副研究员Tel:13951791063E-mail:zhanggenyuan63@126.com
  • 相关文献

参考文献3

二级参考文献69

  • 1Kryger M,Roth T,Wang-Weigand S,et al.The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease[J].Sleep Breath,2009,13(1):79-84.
  • 2Bourne R S,Mills G H,Minelli C.Melatonin therapy to improve nocturnal sleep in critically ill patients:encouraging results from a small randomised controlled trial[J].Crit Care,2008,12(2):R52-R60.
  • 3Greenblatt D J,Harmatz J S,Karim A.Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon,a hypnotic agent acting via melatonin receptors MT1 and MT2[J].J Clin Pharmacol,2007,47(4):485-496.
  • 4Mini L,Wang-Weigand S,Zhang J.Ramelteon 8 mg/d versus placebo in patients with chronic insomnia:post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect[J].Clin Ther,2008,30(7):1316-1323.
  • 5Richardson G S,Zammit G,Wang-Weigand S,et al.Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia:a 1-year,open-label study[J].J Clin Psychiatry,2009,70(4):467-476.
  • 6Zammit G,Erman M,Wang-Weigand S,et al.Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia[J].J Clin Sleep Med,2007,3(5):495-504.
  • 7Mini L J,Wang-Weigand S,Zhang J.Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty[J].Am J Geriatr Pharmacother,2007,5(3):177-184.
  • 8Wang-Weigand S,McCue M,Ogrinc F,et al.Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2:pooled analysis[J].Curr Med Res Opin,2009,25(5):1209-1213.
  • 9Zammit G,Schwartz H,Roth T,et al.The effects of ramelteon in a first-night model of transient insomnia[J].Sleep Med,2009,10(1):55-59.
  • 10Roth T,Seiden D,Wang-Weigand S,et al.A 2-night,3-period,crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia[J].Curr Med Res Opin,2007,23(5):1005-1014.

共引文献33

同被引文献27

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部